|
Compound class:
Antibody
Comment: Donanemab (LY3002813) is a monoclonal antibody developed from the murine monoclonal mE8-IgG2a [1]. It binds to N-terminally, pyroglutamate-modified amyloid β proteins (abbreviated as Aβp3-x or N3pG) which are found extensively in the amyloid plaques of the brains of Alzheimer's disease (AD) patients. The removal of Aβp3-x is being investigated as a novel mechanism to treat AD.
|
